NASDAQ:EPIX
ESSA Pharma Inc. Stock News
$6.43
+0.290 (+4.72%)
At Close: Apr 30, 2024
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
10:08pm, Monday, 13'th Apr 2020
ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has
Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020
07:15pm, Monday, 06'th Apr 2020
NEW YORK, NY / ACCESSWIRE / April 6, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a fourth day of presentations as pa
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
11:00am, Tuesday, 31'st Mar 2020
VANCOUVER and HOUSTON , March 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatm
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
08:00pm, Tuesday, 24'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on Mar
ESSA Pharma (CVE:EPI) Is In A Good Position To Deliver On Growth Plans
01:18pm, Thursday, 19'th Mar 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Medicxi Bolsters and Expands Team with Senior Industry Leaders
08:00am, Tuesday, 17'th Mar 2020
Medicxi, the leading European life sciences investment firm, today announced the appointment of Sanford (Sandy) Zweifach and Paul Sekhri as Venture Partners.
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
12:51am, Friday, 28'th Feb 2020
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the r
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
10:48pm, Thursday, 13'th Feb 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
11:15pm, Monday, 10'th Feb 2020
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
EPIX: Phase 1 Clinical Trial for EPI-7386 to Initiate in 1Q20…
11:15am, Monday, 30'th Dec 2019
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update ESSA Pharma Inc. (EPIX) is a biopharmaceutical company developing treatments for prostate cancer that is no longer re
Hedge Funds Have Never Been This Bullish On ESSA Pharma Inc. (EPIX)
11:41pm, Sunday, 22'nd Dec 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks a
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
10:15pm, Thursday, 19'th Dec 2019
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate
Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors
04:35pm, Thursday, 12'th Dec 2019
Janpix, Inc., a privately-held biopharmaceutical company dedicated to the discovery and development of inhibitors/degraders of Signal Transducer & Activator of Transcription (STAT) proteins for oncolo
